Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | IDO1 | P14902 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14438275 | 0.85 | MEN1 (0.43) | MEN1KMT2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL19862553 | 0.81 | CXCR3 (0.43) | MEN1KMT2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL18685093 | 0.81 | CCR5 (0.48) | MEN1KMT2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL14438295 | 0.81 | MEN1 (0.57) | MEN1KMT2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL12312605 | 0.81 | P2RX7 (0.44) | MEN1KMT2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL14114856 | 0.81 | POLB (0.64) | MEN1KMT2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL25453552 | 0.80 | MEN1 (0.43) | MEN1KMT2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL23754506 | 0.80 | MEN1 (0.68) | MEN1KMT2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL29864910 | 0.80 | MEN1 (0.68) | MEN1KMT2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL23754498 | 0.80 | MEN1 (0.68) | MEN1KMT2ACYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113381006-B | Composite cathode material, preparation method thereof and lithium ion battery | 中国科学院过程工程研究所 | 2022-09-20 | — | — | CN | claimed |
| CN-113381006-B | Composite cathode material, preparation method thereof and lithium ion battery | 中国科学院过程工程研究所 | 2022-09-20 | — | — | CN | disclosed |
| WO-2012136873-A2 | TRPV1 ANTAGONISTS AND USES THEREOF | UNIVERSIDAD MIGUEL HERNÁNDEZ DE ELCHE (ES) | 2012-10-11 | — | — | WO | disclosed |
| US-20090182140-A1 | Alicyclic Heterocyclic Compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-07-16 | — | — | US | disclosed |
| US-7504391-B2 | Selective D1/D5 receptor antagonists for the treatment of obesity and CNS disorders | SCHERING CORPORATION (US) | 2009-03-17 | — | — | US | disclosed |
| US-20070197522-A1 | Dpp-iv inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2007-08-23 | — | — | US | disclosed |
| US-20060160794-A1 | Tachykinin receptor antagonists | ELI LILLY AND COMPANY | 2006-07-20 | — | — | US | disclosed |
| US-20060035958-A1 | Method of treating diabetes and related conditions | MERCK & CO., INC. | 2006-02-16 | — | — | US | disclosed |
| EP-1538903-A2 | METHOD OF TREATING DIABETES AND RELATED CONDITIONS | Merck & Co., Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004024066-A2 | METHOD OF TREATING DIABETES AND RELATED CONDITIONS | MERCK & CO., INC. (US) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182140-A1 | Alicyclic Heterocyclic Compound | CCR4, CCR1, HRH4 | MEN1 4436/4885KMT2A 1211/4885CYP1A2 1309/4885 |
| US-20060160794-A1 | Tachykinin receptor antagonists | TACR1, TACR2, PROKR1 | MEN1 824/4885KMT2A 1262/4885CYP1A2 3029/4885 |
| US-20070197522-A1 | Dpp-iv inhibitors | DPP7, DPP4, DPP3 | MEN1 2811/4885KMT2A 3141/4885CYP1A2 1188/4885 |
| US-20060035958-A1 | Method of treating diabetes and related conditions | GLP1R, GPR119, GCGR | MEN1 4082/4885KMT2A 3570/4885CYP1A2 682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.